Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 6
2007 10
2008 3
2009 4
2010 5
2011 4
2012 2
2013 2
2014 1
2015 2
2016 3
2017 3
2018 1
2019 5
2020 27
2021 37
2022 37
2023 41
2024 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. Wedemeyer H, et al. Among authors: merle u. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. N Engl J Med. 2023. PMID: 37345876 Free article. Clinical Trial.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
Reply to Fernández-de-las-Peñas.
Seessle J, Waterboer T, Freund C, Müller B, Merle U. Seessle J, et al. Among authors: merle u. Clin Infect Dis. 2022 Aug 24;75(1):e1209-e1210. doi: 10.1093/cid/ciac008. Clin Infect Dis. 2022. PMID: 34989791 No abstract available.
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Wedemeyer H, et al. Among authors: merle u. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
Excessive copper impairs intrahepatocyte trafficking and secretion of selenoprotein P.
Schwarz M, Meyer CE, Löser A, Lossow K, Hackler J, Ott C, Jäger S, Mohr I, Eklund EA, Patel AAH, Gul N, Alvarez S, Altinonder I, Wiel C, Maares M, Haase H, Härtlova A, Grune T, Schulze MB, Schwerdtle T, Merle U, Zischka H, Sayin VI, Schomburg L, Kipp AP. Schwarz M, et al. Among authors: merle u. Nat Commun. 2023 Jun 13;14(1):3479. doi: 10.1038/s41467-023-39245-3. Nat Commun. 2023. PMID: 37311819 Free PMC article.
Clinical features of Wilson disease.
Stremmel W, Merle U, Weiskirchen R. Stremmel W, et al. Among authors: merle u. Ann Transl Med. 2019 Apr;7(Suppl 2):S61. doi: 10.21037/atm.2019.01.20. Ann Transl Med. 2019. PMID: 31179298 Free PMC article. Review.
[Microvascular changes in COVID-19].
Wagner WL, Hellbach K, Fiedler MO, Salg GA, Wehrse E, Ziener CH, Merle U, Eckert C, Weber TF, Stiller W, Wielpütz MO, Dullin C, Kenngott HG, Schlemmer HP, Weigand MA, Schirmacher P, Longerich T, Kauczor HU, Kommoss FK, Schwab C. Wagner WL, et al. Among authors: merle u. Radiologe. 2020 Oct;60(10):934-942. doi: 10.1007/s00117-020-00743-w. Radiologe. 2020. PMID: 32857175 Free PMC article. Review. German.
suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury.
Nusshag C, Wei C, Hahm E, Hayek SS, Li J, Samelko B, Rupp C, Szudarek R, Speer C, Kälble F, Schaier M, Uhle F, Schmitt FC, Fiedler MO, Krautkrämer E, Cao Y, Rodriguez R, Merle U, Eugen-Olsen J, Zeier M, Weigand MA, Morath C, Brenner T, Reiser J. Nusshag C, et al. Among authors: merle u. JCI Insight. 2023 Apr 10;8(7):e165740. doi: 10.1172/jci.insight.165740. JCI Insight. 2023. PMID: 37036003 Free PMC article.
193 results